Manollia

Lisdexamfetamine dimesylate, the active ingredient in Manollia, is a central nervous system stimulant presented as an oral dosage form for oral use. It is indicated for the treatment of attention deficit hyperactivity disorder and binge eating disorder in children, adolescents, and adults.

GNH USA supplies Manollia as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable global distribution.

Manollia (lisdexamfetamine) acts on central nervous system pathways that regulate attention, impulse control, and appetite.

- Attention deficit hyperactivity disorder (ADHD): improves attention, reduces hyperactivity and impulsivity in children, adolescents, and adults. - Binge eating disorder: decreases the number of binge‑eating episodes and helps control food intake.

Like all central nervous system stimulants, lisdexamfetamine may cause a range of adverse reactions.

Common Side Effects: - Decreased appetite - Insomnia - Dry mouth - Headache

Serious or Rare Side Effects: - Cardiovascular events such as elevated blood pressure or tachycardia - Psychiatric symptoms including new or worsening psychosis or mania - Severe allergic reactions, for example anaphylaxis or extensive skin rash

Before prescribing Manollia, clinicians should evaluate several safety aspects. - Cardiovascular assessment: evaluate heart rate and blood pressure before initiating therapy. - Psychiatric evaluation: monitor for emergence of anxiety, aggression, or psychotic symptoms. - Growth monitoring: track height and weight in pediatric patients regularly. - Potential for abuse: prescribe only when benefits outweigh risk of dependence. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and light.

Lisdexamfetamine can interact with several medication classes, requiring careful management.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): concurrent use can cause hypertensive crisis. - Strong CYP2D6 inhibitors: may increase lisdexamfetamine exposure and adverse effects.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: stimulant may reduce their efficacy, requiring blood pressure monitoring. - Serotonergic drugs (e.g., SSRIs, SNRIs): may increase risk of serotonin syndrome. - Acid‑reducing agents (antacids, H2 blockers): can alter absorption, monitor therapeutic response.